Linagliptin; Uses, Dosage, Side Effects, Drug Interactions

Linagliptin; Uses, Dosage, Side Effects, Drug Interactions

Linagliptin is a Dipeptidyl Peptidase 4 Inhibitor. The mechanism of action of linagliptin is as a Dipeptidyl Peptidase 4 Inhibitor.Linagliptin is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. The inhibition of DPP-4 by linagliptin appears to be longer lasting than that by some other DPP-4 inhibitors tested.

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [Wikipedia]. Two pharmacological characteristics that sets linagliptin apart from other DPP-4 inhibitors is that it has a non-linear pharmacokinetic profile and is not primarily eliminated by the renal system. FDA approved on May 2, 2011. In comparison, sitagliptin, saxagliptin, and vildagliptin have an IC50 of 19, 50, and 62 nM respectively. A dose of 2.5 and 5 mg reduces the activity of DPP-4 by 72.7% and 86.1% from baseline respectively in healthy male subjects. In diabetes patients, a dose of 5 and 10 mg inhibits >90% of DPP-4. Linagliptin is also selectively inhibited DPP-4 as indicated by the lack of DPP-8 or DPP-9 inhibition at therapeutic exposures in vitro.

Mechanism of Action of Linagliptin

Linagliptin belongs to a class of drugs called DPP-4 inhibitors. DPP-4 inhibitors prevent the hormone incretin from being degraded, allowing insulin to be released from the pancreatic beta cells. While incretin remains in the blood stream, the pancreas is stimulated to produce more insulin. Meanwhile, glucagon release from the pancreas is staggered, preventing glucose level increase. In other words, linagliptin, along with diet and exercise, can help the body produce more insulin and lower blood glucose. Managing blood sugar can mean a lower HbA1c, an index for glycemia control that theoretically correlates with glucose level in the blood.

You Might Also Like   Roxithromycin; Uses, Dosage, Side Effects, Drug Interactions


Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Thus, linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin in a glucose-dependent manner and decreasing the levels of glucagon in the circulation. Both incretin hormones are involved in the physiological regulation of glucose homeostasis. Incretin hormones are secreted at a low basal level throughout the day and levels rise immediately after meal intake. GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta-cells in the presence of normal and elevated blood glucose levels. Furthermore, GLP-1 also reduces glucagon secretion from pancreatic alpha-cells, resulting in a reduction in hepatic glucose output.

Indications of Linagliptin

  • Type 2 Diabetes Mellitus
  • The drug can effectively reduce blood sugar
  • Linagliptin is used for the management of type 2 diabetes mellitus.
  • Trajenta is indicated in adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control as monotherapy
  • when metformin is inappropriate due to intolerance or contraindicated due to renal impairment.
  • Combination therapy in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Contra-Indications of Linagliptin

  • Low blood sugar
  • Pituitary hormone deficiency
  • Decreased Function of the Adrenal Gland
  • Inadequate Vitamin B12
  • Excess Body Acid
  • Extreme Loss of Body Water
  • Habit of Drinking Too Much Alcohol
  • Alcohol Intoxication
  • Heart Attack
  • Suddenly serious symptoms of heart failure
  • Liver Problems
  • Recent operation
  • Fever
  • Shock
  • Severe Vomiting
  • Severe Diarrhea
  • Serious Lack of Oxygen in the Blood
  • Weakened Patient
  • Injury
  • Sepsis Syndrome
  • X-Ray Study with Intravenous Iodine Contrast Agent
  • Chronic kidney disease stage 3B (moderate)
  • Chronic kidney disease stage 4 (severe)
  • Chronic kidney disease stage 5 (failure)
  • Kidney disease with a likely reduction in kidney function
  • Pancreatitis
You Might Also Like   Benzodiazepines; Types, Uses, Contra Indications, Side Effects, Interactions

Dosage of Linagliptin

Strengths: 5 mg

Diabetes Type 2

  • Recommended dose: 5 mg orally once a day

Side Effects of Linagliptin

Most common

More common

Less common

  • Abnormal stools
  • bad, unusual, or unpleasant (after) taste
  • change in taste
  • difficulty with moving
  • discoloration of the fingernails or toenails
  • flu-like symptoms
  • joint pain
  • rash
  • runny nose
  • sneezing
  • stuffy nose
  • swollen joints

Drug Interactions of Linagliptin

Linagliptin may interact with following drugs, supplements & may decrease the efficacy of the drug

Pregnancy & Lactation of Linagliptin

FDA Pregnancy Category B


This medication should not be used during pregnancy unless the benefits outweigh the risks. If you become pregnant while taking this medication, contact your doctor immediately.

You Might Also Like   Tiludronic Acid; Uses, Dosage, Side Effects, Interactions, Pragnancy


It is not known if linagliptin passes into breast milk. If you are a breastfeeding mother and are taking this medication, it may affect your baby. Talk to your doctor about whether you should continue breastfeeding.





If the article is helpful, please Click to Star Icon and Rate This Post!
[Total: 0 Average: 0]

About the author

Translate »